Adawi Kamal
SEC CIK 1788393 · EDGAR
BoughtSold
Most active insiders at FATE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Valamehr Bahram | Pres, CEO, Dir | — | $168.1K |
| 2 | TAHL CINDY | See Remarks | — | $154.7K |
| 3 | Adawi Kamal | CFO | — | — |
| 4 | Redmile Group, LLC | Dir, 10% | — | — |
| 5 | EPSTEIN ROBERT S | Dir | — | — |
| 6 | RASTETTER WILLIAM H | Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-16 | 2026-01-15 | FATE | FATE THERAPEUTICS INC | Adawi Kamal | CFO | A - Grant | $0.00 | +25.0K | 100.0K | +33% | $0 |
| D | 2025-10-21 | 2025-10-20 | FATE | FATE THERAPEUTICS INC | Adawi Kamal | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
| M | 2024-03-06 | 2024-03-04 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | S - Sale | $1.91 | -12.8K | 247.2K | -5% | -$24.4K |
| 2024-02-22 | 2024-02-20 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | A - Grant | $0.00 | +75.0K | 256.5K | +41% | $0 | |
| 2024-02-08 | 2024-02-06 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | S - Sale | $1.95 | -6,738 | 181.5K | -4% | -$13.1K | |
| 2023-03-03 | 2023-03-02 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | S - Sale | $2.30 | -3,667 | 188.3K | -2% | -$8,434 | |
| 2023-03-01 | 2023-02-27 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | A - Grant | $0.00 | +100.0K | 191.9K | +109% | $0 | |
| 2023-02-10 | 2023-02-08 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | S - Sale | $2.69 | -5,821 | 91.9K | -6% | -$15.7K | |
| 2022-03-02 | 2022-03-01 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | F - Tax | $7.12 | -3,241 | 97.8K | -3% | -$23.1K | |
| 2022-02-08 | 2022-02-04 | XGN | EXAGEN INC. | Adawi Kamal | CFO, Corp. Sec | A - Grant | $0.00 | +63.5K | 101.0K | +169% | $0 |
Purchase Sale Sale after option exercise All abbreviations